Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.83 USD
-0.16 (-5.35%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.82 -0.01 (-0.35%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TSHA 2.83 -0.16(-5.35%)
Will TSHA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSHA
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Other News for TSHA
Fell Below 50 Day Moving Average appears for TSHA after 5.35% move
Is TSHA set to rally? Directional Movement Crossover Bullish shows up after rising 3.1%
What's Driving the Market Sentiment Around Taysha Gene Therapies?
TSHA forms 50 Day Moving Average Support on September 18
Is TSHA ready to move lower? 20 Day Moving Average Resistance shows up after tumbling 5.96%